Meningococcal glycoconjugate vaccines

Human Vaccines

Volumn 7, Issue 2, 2011, Pages 170-182

  Gasparini, Roberto ^a   Panatto, Donatella ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Glycoconjugate vaccines; Immunity; Meningococcal disease; Meningococcus; Neisseria meningitidis; Vaccination

Indexed keywords

ALUMINUM PHOSPHATE; BACTERIAL POLYSACCHARIDE; BACTERIAL VACCINE; DIPHTHERIA TOXOID; DIPHTHERIA TOXOID CRM197; GLYCOCONJUGATE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HAEMOPHILUS VACCINE; HIB TYPE B POLYSACCHARIDE CONJUGATED TETANUS TOXOID WITH MENC POLYSACCHARIDE CONJUGATED TETANUS TOXOID; MENAFRIVAC; MENINGITIS VACCINE; MENINGIVAC; MENINGOCOCCUS VACCINE; MENITORIX; MENIVACT; NEIS VAC C; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE;

BACTERIAL INFECTION; DRUG APPROVAL; DRUG SAFETY; EPIDEMIC; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNITY; IMMUNOGENICITY; INFECTION CONTROL; INFECTION RISK; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; REVIEW; SINGLE DRUG DOSE; UNITED STATES; VACCINATION;

BACTERIAL CAPSULES; GLYCOCONJUGATES; HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; VACCINES, CONJUGATE;

EID: 79952498476     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.2.13717     Document Type: Review

References (126)

1. Viesseux G. Mémoire sur la maladie qui a régné à Genève au printemps de 1805. J Med Chir Farm 1805; 11:143-82.
2. Wu HM, Harcourt BH, Hatcher CP, Wei SC, Novak RT, Wang X, et al. Emergence of ciprofloxacin-resistant Neisseria meningitidis in North America. N Engl J Med 2009; 360:886-92.
3. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364:365-7. (Pubitemid 38970013)
4. European Union Invasive Bacterial Infections Surveillance (EU-IBIS) Network. Invasive Neisseria meningitidis in Europe 2006. London: Health Protection Agency 2007; http://www.euibis.org/documents/2006-meningo.pdf. Accessed on May 13 2010.
5. Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000; 19:187-95. (Pubitemid 30167436)
6. Knuf M, Szenborn L, Moro M, Petit C, Bermal N, Bernard L, et al. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenze protein D conjugate vaccine (PHiD-CV). Pediatr Infect Dis J 2009; 28:97-108.
7. Dinleyici EC, Yargic ZA. Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine. Expert Rev Vaccines 2009; 8:977-86.
8. Advisory Committee on Immunization Practices (ACIP). Prevention and Control of Meningococcal Disease. MMWR 2005; 54:1-21.
9. Center for Disease Control and Prevention. Licensure of a meningococcal Conjugate Vaccine (Menveo) and Guidance for Use - Advisory Committee on Immunization Practices 2010; Available on-line: http://www.cdc.gov/mmwr/preview/ mmwrhtml/mm5909a5.htm. Accessed on May 13 2010.
10. European Medicine Agency. EPARs for authorised medicinal products for human use - Menveo. Available on: http://www.ema.europa.eu/humandocs/Humans/ EPAR/menveo/menveo.htm. Accessed on May 13 2010.
11. th Edition. Philadelphia: Saunders 2008; 399-434.
12. Pollard AJ, Levin M. Vaccines for prevention of meningococcal disease. Pediatr Infect Dis J 2000; 19:333-44.
13. Gold R, Goldschneider I, Lepow ML, Draper TF, Randolph M. Carriage of Neisseria meningitidis and Neisseria lactamica in infants and children. J Infect Dis 1978; 137:112-21.
14. Caugant DA, Maiden MC. Meningococcal carriage and disease - population biology and evolution. Vaccine 2009; 27:64-70.
15. Stephens DS, Greenwood B, Brandtzaeg P. Epidemic meningitis, meningococcaemia and Neisseria meningitidis. Lancet 2007; 369:2196-210.
16. Stephens DS. Conquering the meningococcus. FEMS Microbiol Rev 2007; 31:3-14. (Pubitemid 46058815)
17. Lo H, Tang CM, Exley RM. Mechanisms of avoidance of host immunity by Neisseria meningitidis and its effect on vaccine development. Lancet Infect Dis 2009; 9:418-27.
18. Kolb-Mäurer A, Unkmeir A, Kämmerer U, Hübner C, Leimbach T, Stade A, et al. Interaction of Neisseria meningitidis with human dendritic cells. Infect Immun 2001; 69:6912-22.
19. Unkmeir A, Kämmerer U, Stade A, Hübner C, Haller S, Kolb-Mäurer A, et al. Lipooligosaccharide and polysaccharide capsule: virulence factors of Neisseria meningitidis that determine meningococcal interaction with human dendritic cells. Infect Immun 2002; 70:2454-62.
20. Rosenstein NE, Perkins BA, Stephens DS, Lefkowitz L, Cartter ML, Danila R, et al. The changing epidemiology of meningococcal disease in the United States 1992-1996. J Infect Dis 1999; 180:1894-901.
21. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 2009; 27:51-63.
22. Pizza M, Scarlato V, Masignani V, Giuliani MM, Aricò B, Comanducci M, et al. Identification of vaccine candidates against serogroup B meningococcus by wholegenome sequencing. Science 2000; 287:1816-20.
23. Rappuoli R. Reverse vaccinology. Curr Opin Microbiol 2000; 3:445-50.
24. Fletcher LD, Bernfield L, Barniak V, Farley JE, Howell A, Knauf M, et al. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect Immun 2004; 72:2088-100.
25. Zhu D, Barniak V, Zhang Y, Green B, Zlotnick G. Intranasal immunization of mice with recombinant lipidated P2086 protein reduces nasal colonization of group B Neisseria meningitidis. Vaccine 2006; 24:5420-5. (Pubitemid 43831373)
26. Richmond P, Marshall H, Nissen MD, Lambert S, Jones T, Gruber W, Arora A. A randomized, observer-blinded, active-control, phase 1 trial of meningococcal serogroup B rLP2086 vaccine in healthy children and adolescents aged 8 to 14 years. Poster presented at: 16th International Pathogenic Neisseria Conference, Rotterdam, the Netherlands 2008; 212.
27. Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010; 362:1511-20.
28. Trotter CL, Maiden MC. Meningococcal vaccines and herd immunity: lessons learned from serogroup C conjugate vaccination programs. Expert Rev Vaccines 2009; 8:851-61.
29. Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2001; 344:1378-88.
30. Cartwright K. Meningococcal carriage and disease. In: Cartwright K, Ed. Meningococcal Disease. New York: John Wiley & Sons Ltd 1995; 115-46.
31. Advisory Committee on Immunization Practices (ACIP). Prevention and control meningococcal disease. Recommendations of the AICP. MMWR Recomm Rep 2000; 49:1-10.
32. WHO. Meningococcal meningitis. Fact Sheet No.141.2003. http://www.who.int/mediacenter/factsheets/fs141/en/index.html. Accessed on May 13 2010.
33. Erickson L, De Wals P. Complications and sequelae of meningococcal disease in Quebec, Canada 1990-1994. Clin Infect Dis 1998; 26:1159-64.
34. Goldacre MJ, Roberts SE, Yeates D. Case fatality rates for meningococcal disease in an English population 1963-98: database study. BMJ 2003; 327:596-7.
35. Kimmel SR. Prevention of meningococcal disease. Am Fam Physician 2005; 72:2049-56. (Pubitemid 41653084)
36. Sophian A, Black J. Prophylactic vaccination against epidemic meningitis. JAMA 1912; 59:527-32.
37. Gates FL. A report on antimeningitis vaccination and observations on agglutinins in the blood of chronic meningococcus carriers. J exp Med 1918; 28:449-74.
38. Artenstein MS, Schneider H, Tingley MD: Meningococcal infections. 1. Prevalence of serogroups causing disease in US Army personnel in 1964-70. Bull World Health Organ 1971; 45:275-8.
39. Miller JW, Siess EE, Feldman HA: In vivo and in vitro resistance to sulfadiazine in strains of Neisseria meningitidis. Jama 1963; 186:139-41.
40. Gotschlich EC, Liu TY, Artenstein MS. Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B and group C meningococcal polysaccharides. J Exp Med 1969; 129:1349-65.
41. Gotschlich EC, Goldschneider I, Artenstein MS. Human immunity to the meningococcus. IV. Immunogenicity of group A and group C meningococcal polysaccharides in human volunteers. J Exp Med 1969; 129:1367-84.
42. Mäkelä PH, Käyhty H, Weckström P, Sivonen A, Renkonen OV. Effect of group-A meningococcal vaccine in army recruits in Finland. Lancet 1975; 2:883-6.
43. Peltola H, Mäkelä H, Käyhty H, Jousimies H, Herva E, Hällström K, et al. Clinical efficacy of meningococcus group A capsular polysaccharide vaccine in children three months to five years of age. N Engl J Med 1977; 297:686-91. (Pubitemid 8208235)
44. Rosenstein N, Levine O, Taylor JP, Evans D, Plikaytis BD, Wenger JD, Perkins BA. Efficacy of meningococcal vaccine and barriers to vaccination. JAMA 1998; 279:435-9. (Pubitemid 28082252)
45. Griffiss JM, Brandt BL, Broud DD. Human immune response to various doses of group Y and W135 meningococcal polysaccharide vaccines. Infect Immun 1982; 37:205-8. (Pubitemid 12095205)
46. Ambrosch F, Wiedermann G, Crooy P, George AM. Immunogenicity and side-effects of a new tetravalent meningococcal polysaccharide vaccine. Bull World Health Organ 1983; 61:317-23. (Pubitemid 13061110)
47. Poland GA. Prevention of meningococcal Disease. Current Use of Polysaccharide and conjugate vaccines. CID 2010; 50:45-53.
48. Bulukha OO, Rosenstein N. National Center for Infectious Diseases, Center for Disease Control and Prevention. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMRW Recomm Rep 2005; 54:1-21.
49. Biselli R, Fattorossi A, Matricardi PM, Nisini R, Stroffolini T, D'Amelio R. Dramatic reduction of meningococcal meningitis among military recruits in Italy after introduction of specific vaccination. Vaccine 1993; 11:578-81. (Pubitemid 23130870)
50. Robbins JB, Schneerson R, Gotschlich EC, Mohammed I, Nasisi A, Chippaux JP, et al. Menigococcal meningitis in sub-Saharan Africa: the case for mass and routine vaccination with available polysaccharide vaccines. Bull World Health Organ 2003; 81:745-50. (Pubitemid 37429075)
51. Birmingham ME, Lewis RF, Perea W, Nelson CB, Kabore A, Tarantola D. Routine vaccination with polysaccharide meningococcal vaccines is an ineffective and possibly harmful strategy. Bull World Health Organ 2003; 81:751-5.
52. Twumasi PA Jr, Kumah S, Leach A, O'Dempsey TJ, Ceesay SJ, Todd J, et al. A trial of a group A plus group C meningococcal polysaccharide-protein conjugate vaccine in African infants. J Infect Dis 1995; 171:632-8.
53. Lieberman JM, Chiu SS, Wong VK, Partidge S, Chang SJ, Chiu CY, et al. Safety and immunogenicity of a serogroups A/C Neisseria meningitidis oligosaccharideprotein conjugate vaccine in young children. A randomized controlled trial. JAMA 1996; 275:1499-503.
54. Avery OT, Goebel WF. Chemo-immunological studies on conjugate carbohydrate proteins. II. Immunological specificity of synthetic sugar protein antigen. J Exp Med 1929; 50:533-50.
55. Ada G, Isaacs D. Carbohydrate-protein conjugate vaccines. Clin Microbiol Infect 2003; 9:79-85. (Pubitemid 36527051)
56. Lindberg AA. Glycoprotein conjugate vaccines. Vaccine 1999; 17:28-36.
57. Breukels M, Zandvoort A, Van Den Dobblesteen GP, et al. Pneumococcal conjugate vaccines overcome splenic dependency of antibody response to pneumococcal polysaccharides. Infect Immun 2001; 69:7583-7. (Pubitemid 33086585)
58. Stein KE. Thymus-independent and thymus-dependent response to polysaccharide antigens. J Infect Dis 1992; 165:49-52.
59. Adams WG, Deaver KA, Cochi SL, et al. Decline of childhood Haemophilus influenze type b (Hib) disease in the Hib vaccine era. JAMA 1993; 269:221-6.
60. Peltola H, Kipli T, Anttila M. Rapid disappearance of Haemophilus influenze type b meningitis after routine childhood immunisation with conjugate vaccines. Lancet 1992; 340:592-4.
61. Schuchat A, Robinson K, Wenger JD, et al. Bacterial meningitis in the United States in 1995. N Engl J Med 1997; 337:970-6.
62. Barbour ML, Mayon-White RT, Coles C, Crook DWM, Moxon ER. The impact of conjugate vaccine on carriage of Haemophilus influenze type b. J Infect Dis 1995; 171:93-8.
63. Jonsdotir KE, Steingrimsson O, Olafsson O. Immunisation in infants in Iceland against Haemophilus influenze type b. Lancet 1992; 340:252-3.
64. Prymula R, Schuerman L. 10-valent pneumococcal nontypeable Haemophilus influenze PD conjugate vaccine: Synflorix. Expert Rev Vaccines 2009; 8:1479-500.
65. Vesikari T, Wysocki J, Chevallier B, Karvonen A, Czajka H, Arsène JP, et al. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenze protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine. Pediatr Infect Dis J 2009; 28:66-76.
66. Lin FYC, Vo AH, Khiem HB, et al. The efficacy of a Samonella typhi Vi conjugate vaccine in two to five year-old children. N Engl J Med 2001; 344:1263-9.
67. Baker CJ, Paoletti LC, Rench MA, et al. Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B streptococcus in healthy women. J Infect Dis 2000; 182:1129-38.
68. Shinenfield H, Black S, Fattom A, et al. Use of a staphylococcus aureus conjugate vaccine in patients receiving heamodialysis. N Engl J Med 2002; 346:491-6. (Pubitemid 34441740)
69. Cryz SR Jr, Que JO, Cross S, Furer E. Synthesis and characterisation of a polyvalent Escherichia coli O-polysaccharide-toxin A conjugate vaccine. Vaccine 1995; 13:449-53.
70. Pollard AJ, Perrett KP, Beverly PC. Mantaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 2009; 9:213-20.
71. Harrison LH. Vaccine prevention of meningococcal disease: making slow progress. Clin Infect Dis 2006; 43:1395-7. (Pubitemid 44845638)
72. Ramsay ME, Andrews N, Kaczmarski EB, Miller E. Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. Lancet 2001; 357:195-6. (Pubitemid 32108093)
73. Trotter CL, Chandra M, Cano R, Larrauri A, Ramsay ME, Brehony C, et al. A surveillance network for meningococcal disease in Europe. FEMS Microbiol Rev 2007; 31:27-36. (Pubitemid 46058817)
74. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 2004; 364:365-7. (Pubitemid 38970013)
75. Gray SJ, Trotter CL, Ramsay ME, Guiver M, Fox AJ, Borrow R, et al. Epidemiology of meningococcal disease in England and Wales 1993/94 to 2003/04: contribution and experiences of the Meningococcal Reference Unit. J Med Microbiol 2006; 55:887-96.
76. Maiden MC, Ibarz-Pavòn AB, Urwin R, Gray SJ, Andrews NJ, Clarke SC, et al. Impact of meningococcal serogroup C conjugate vaccis on carriage and herd immunity. J Infect Dis 2008; 197:737-43. (Pubitemid 351364476)
77. th Annual Meeting of ESPID - Nice, France, May 4-8 2010; 26.
78. Borrow R, Andrews N, Findlow H, Waight P, Southern J, Crowley-Luke A, et al. Kinetics of antibody persistence following administration of a combination meningococcal serogroup C and Haemophilus influenze type b conjugate vaccine in healthy infants in the United Kingdom primed with a monovalent meningococcal serogroup C vaccine. Clin Vaccine Immunol 2010; 17:154-9.
79. Keyserling H, Papa T, Koranyi K, Ryall R, Bassily E, Bybel MJ, et al. Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch Pediatr Adolesc Med 2005; 159:907-13. (Pubitemid 41423328)
80. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C congiugate vaccine by using efficacy estimates from postlicensure surveillance in England. Clin Diagn Lab Immunol 2003; 10:780-6. (Pubitemid 37129487)
81. Food and Drug Administration. Product approval information licensing action. Rockville, MD: US Department of Health and Human Services, Food and Drugs Administration, Center for Biologics Evaluation and Research 2005. Available at http://www.fda.gov/cber/products/mpdtave011405.htm.htm.
82. Pichichero M, Casey J, Blatter M, Rothstein E, Ryall R, Bybel M, et al. Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two to ten year-old children. Pediatr Infect Dis J 2005; 24:57-62. (Pubitemid 40353317)
83. Rennels M, King J Jr, Ryall R, Papa T, Froeschle J. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr Infect Dis J 2004; 23:429-35. (Pubitemid 38621482)
84. Rennels M, King J Jr, Ryall R, Manoff S, Papa T, Weddle A, Froeschle J. Dose escalation, safety and immunogenicity study of a tetravalent meninogococcal polysaccharide diphtheria conjugate vaccine in toddlers. Pediatr Infect Dis J 2002; 21:978-9. (Pubitemid 35176163)
85. Finn A. Bacterial polysaccharide-protein conjugate vaccines. Br Med Bull 2004; 70:1-14. (Pubitemid 40069369)
86. Center for Disease Control and Prevention. Update Guillain-Barre syndrome among recipients of menactra meningococcal conjugate vaccine, United States, June 2005. MMWR 2006; 55:1120.
87. Center for Disease Control and Prevention. Recommended immunization schedules for persons aged 0 through 18 years - United States 2009. MMWR 2009; 57:1-4.
88. Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu LM, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008; 299:173-84.
89. Black S, Klein NP, Shah J, Bedell L, Karsten A, Dull PM. Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age. Vaccine 2010; 28:657-63.
90. Jackson LA, Baxter R, Reisinger K, Karsten A, Shah J, Bedell L, et al. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis 2009; 49:1-10.
91. th Annual Meeting of ESPID - Nice, France, May 4-8 2010; 380.
92. Gasparini R, Conversano M, Bona G, Gabutti G, Anemona A, Dull PM, et al. Randomized trial on the safety, tolerability and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria and acellular pertussis vaccine in adolescents and young adults. Clin Vaccine Immunol 2010; 17:537-44.
93. Arguedas A, Soley C, Loaiza C, Rincon G, Guevara S, Perez A, et al. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine 2010; 28:3171-9.
94. Ostergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D. Immunogenicity, reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 2009; 27:161-8.
95. th Annual Meeting of ESPID - Nice, France, May 4-8 2010; 391.
96. th Annual Meeting of ESPID - Nice, France, May 4-8 2010; 398.
97. th Annual Meeting of ESPID - Nice, France, May 4-8 2010; 432.
98. US National Institutes of Health Clinical Trials Delivered via RSS. Study on the impact of Vaccination with a Conjugate Vaccine on Meningococcal Carriage. Available on: http://clinicaltrialsfeeds.org/clinical-trials/show/ NCT01119482.
99. WHO - Fact sheets. Development of mew vaccines. Available on: http://www.who.int/mediacentre/factsheets/fs289/en/.
100. MVP - Meningitis Vaccine Project. Timeline. Put a end to a century of epidemics. Available on: http://www.meningvax.org/timeline.php.
101. Kshirsagar N, Mur N, Thatte U, Gogtay N, Viviani S, Préziosi MP, et al. Safety, immunogenicity and antibody persistence of a new meningococcal group A conjugate vaccine in healthy Indian adults. Vaccine 2007; 3:25:101-7.
102. WHO - News releases. Improved meningitis vaccine for Africa could signal end to deadly scourge. Available on: http://www.who.int/mediacentre/news/ releases/2007/pr28/en/.
103. UNICEF WCARO. African Health Ministries to introduce new vaccines to prevent deadly meningitis epidemics. Available on: httpo://www.unicef.org/wcaro/ 2009-2615.html.
104. Moszynski P. New meningitis A vaccine is hailed as a " breakthrough" for 430 million people at risk. BMJ 2010; 3552.
105. Miller E, Salisbury D, Ramsay M. Planning, registration and implementation of an immunisation campaign against meningococcal serogroup C disease in the UK: a success story. Vaccine 2001; 20:58-67.
106. Health Protection Agency. Guidance for public health management of meningococcal disease in the UK Health Protection Agency Meningococcus Forum Updated August 2006. Available on: http://www.hpa.org.uk/web/HPAwebFile/HPAweb- C/1194947389261. Accessed on May 19 2010.
107. Center for Disease Control and Prevention (CDC). Prevention and Control of Meningococcus Disease. Recommendations of the Advisory Committee on Immunization Practices (AICP). MMWR 2005; 54:1-21.
108. Center for Disease Control and Prevention (CDC). Updated Recommendations from the Advisory Committee on Immunization Practices (AICP) for Revaccination of Persons at Prolonged Increased Risk for Meningococcal Disease. MMWR 2009; 58:1042-3.
109. Bruce MG, Rosenstein NE, Capparella JM, Shutt KA, Perkins BA, Collins M. Risk factors for meningococcal disease in college students. JAMA 2001; 286:688-93. (Pubitemid 33010361)
110. Harrison LH, Dwyer DM, Maples CT, Billmann L. Risk of meningococcal infection in college students. JAMA 1999; 281:1906-10. (Pubitemid 29242804)
111. CDC. Laboratory-acquired meningococcal disease - United States 2000. MMWR 2002; 51:141-4.
112. Brundage JF, Zollinger WD. Evolution of meningococcal disease epidemiology in the US Army. In: Vedros NA, Ed. Evolution of meningococcal disease. Boca Raton, FL: CRC Press Inc 1987; 1:5-25.
113. Riedo FX, Plikaytis BD, Broome CV. Epidemiology and prevention of meningococcal disease. Pediatr Infect Dis J 1995; 14:643-57.
114. Figueroa JE, Densen P. Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 1991; 4:359-95. (Pubitemid 21920404)
115. Francke EL, Neu HC. Postsplenectomy infection. Surg Clin North Am 1981; 61:135-55. (Pubitemid 12079209)
116. Center for Disease Control and Prevention (CDC). Licensure of a Meningococcal Conjugate Vaccine (Menveo) and Guidance for use - Advisory Committee on Immunization Practices (ACIP) 2010. MMWR 2010; 59:273.
117. National Advisory Committee on Immunization (NACI). Statement on recommended use of meningococcal vaccines. CCDR 2001; 27:2-36.
118. National Advisory Committee on Immunization (NACI). Update on meningococcal C conjugate vaccines. CCDR 2005; 31:1-4.
119. D'Ancona F, Alfonsi V, Caporali M, Ranghiasci A, Ciofi degli Atti ML. Pneumococcal conjugate, meningococcal C and varicella vaccination in Italy. Euro Surveill 2007; 12.
120. Beernink PT, Caugant DA, Welsch JA, Koeberling O, Granoff DM. Meningococcal factor H-binding protein variants expressed by epidemic capsular group A, W-135 and X strains from Africa. J Infect Dis 2009; 199:1360-8.
121. Pastor P, Medley FB, Murphy TV. Meningococcal disease in Dallas County, Texas: results of a six-year population-based study. Pediatr Infect Dis J 2000; 19:324-8.
122. Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, et al. Changes in Neisseria meningitidis disease epidemiology in the United States 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010; 50:184-91.
123. Pelton SI. Conjugate Meningococcal Vaccines: Lifesaving or Inefficient Use or Both - No easy Answer. CID 2010; 50:192-3.
124. De Wals P. Immunization strategies for the control of serogroup C meningococcal disease in developed countries. Expert Rev Vaccines 2006; 5:269-75. (Pubitemid 44179956)
125. Trotter C, Borrow R, Andrews N, Miller E. Seroprevalence of meningococcal serogroup C bactericidal antibody in England and Wales in the prevaccination era. Vaccine 2003; 21:1094-8. (Pubitemid 36139939)
126. Gasparini R, Rizzetto R, Sasso T, Rizzitelli E, Manfredi P, Risso D, et al. Seroprevalence of bactericidal antibody against Neisseria meningitidis serogroup C in pre-vaccinal era: the Italian epidemiological scenario. Vaccine 2009; 27:3435-8.